Jilin Jian Yisheng Pharmaceutical Co Ltd
Jilin Jian Yisheng Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, wholesale, retail, import, and export of pharmaceutical products in China. The company offers paper packaging products; drugs comprising capsules, injections, tablets, granules, and other drug products; cosmetics; ginseng products; bee products; and food products comprisi… Read more
Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) - Net Assets
Latest net assets as of September 2025: CN¥2.32 Billion CNY
Based on the latest financial reports, Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) has net assets worth CN¥2.32 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.98 Billion) and total liabilities (CN¥658.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.32 Billion |
| % of Total Assets | 77.92% |
| Annual Growth Rate | 13.5% |
| 5-Year Change | 9.44% |
| 10-Year Change | 33.72% |
| Growth Volatility | 72.91 |
Jilin Jian Yisheng Pharmaceutical Co Ltd - Net Assets Trend (2006–2024)
This chart illustrates how Jilin Jian Yisheng Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jilin Jian Yisheng Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual net assets of Jilin Jian Yisheng Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.33 Billion | +0.04% |
| 2023-12-31 | CN¥2.33 Billion | +3.69% |
| 2022-12-31 | CN¥2.25 Billion | +2.33% |
| 2021-12-31 | CN¥2.20 Billion | +3.10% |
| 2020-12-31 | CN¥2.13 Billion | +3.61% |
| 2019-12-31 | CN¥2.06 Billion | +4.69% |
| 2018-12-31 | CN¥1.97 Billion | +3.61% |
| 2017-12-31 | CN¥1.90 Billion | +5.33% |
| 2016-12-31 | CN¥1.80 Billion | +3.21% |
| 2015-12-31 | CN¥1.75 Billion | -0.34% |
| 2014-12-31 | CN¥1.75 Billion | +4.43% |
| 2013-12-31 | CN¥1.68 Billion | +5.51% |
| 2012-12-31 | CN¥1.59 Billion | +4.97% |
| 2011-12-31 | CN¥1.51 Billion | +321.29% |
| 2010-12-31 | CN¥359.40 Million | +27.90% |
| 2009-12-31 | CN¥280.99 Million | +27.79% |
| 2008-12-31 | CN¥219.89 Million | +6.96% |
| 2007-12-31 | CN¥205.59 Million | -13.87% |
| 2006-12-31 | CN¥238.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jilin Jian Yisheng Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 637.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥924.57 Million | 41.36% |
| Common Stock | CN¥330.95 Million | 14.80% |
| Other Components | CN¥980.08 Million | 43.84% |
| Total Equity | CN¥2.24 Billion | 100.00% |
Jilin Jian Yisheng Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Jilin Jian Yisheng Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ãlgerðin Egill SkallagrÃmsson hf.
IC:OLGERD
|
$212.16 Million |
|
FuJian YanJing HuiQuan Brewery Co Ltd
SHG:600573
|
$212.28 Million |
|
Hexagon Composites ASA
PINK:HXGCF
|
$212.30 Million |
|
Accent Group Ltd
AU:AX1
|
$212.31 Million |
|
CII Bridges and Roads Investment JSC
VN:LGC
|
$212.07 Million |
|
Shenyang Huitian Thermal Power Co Ltd
SHE:000692
|
$212.01 Million |
|
Beijing SunwayWorld Science & Technology Co. Ltd.
SHE:301159
|
$211.95 Million |
|
VASTNED BELGIUM S.A.
F:IJX
|
$211.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jilin Jian Yisheng Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,233,163,335 to 2,235,606,654, a change of 2,443,319 (0.1%).
- Net income of 52,086,058 contributed positively to equity growth.
- Dividend payments of 61,635,448 reduced retained earnings.
- Other comprehensive income decreased equity by 181,095,782.
- Other factors increased equity by 193,088,491.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥52.09 Million | +2.33% |
| Dividends Paid | CN¥61.64 Million | -2.76% |
| Other Comprehensive Income | CN¥-181.10 Million | -8.1% |
| Other Changes | CN¥193.09 Million | +8.64% |
| Total Change | CN¥- | 0.11% |
Book Value vs Market Value Analysis
This analysis compares Jilin Jian Yisheng Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.22x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.59x to 1.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.96 | CN¥8.26 | x |
| 2007-12-31 | CN¥0.83 | CN¥8.26 | x |
| 2008-12-31 | CN¥0.88 | CN¥8.26 | x |
| 2009-12-31 | CN¥1.13 | CN¥8.26 | x |
| 2010-12-31 | CN¥1.45 | CN¥8.26 | x |
| 2011-12-31 | CN¥4.85 | CN¥8.26 | x |
| 2012-12-31 | CN¥4.76 | CN¥8.26 | x |
| 2013-12-31 | CN¥4.93 | CN¥8.26 | x |
| 2014-12-31 | CN¥5.21 | CN¥8.26 | x |
| 2015-12-31 | CN¥5.22 | CN¥8.26 | x |
| 2016-12-31 | CN¥5.26 | CN¥8.26 | x |
| 2017-12-31 | CN¥5.45 | CN¥8.26 | x |
| 2018-12-31 | CN¥5.61 | CN¥8.26 | x |
| 2019-12-31 | CN¥5.84 | CN¥8.26 | x |
| 2020-12-31 | CN¥6.03 | CN¥8.26 | x |
| 2021-12-31 | CN¥6.29 | CN¥8.26 | x |
| 2022-12-31 | CN¥6.51 | CN¥8.26 | x |
| 2023-12-31 | CN¥6.75 | CN¥8.26 | x |
| 2024-12-31 | CN¥6.76 | CN¥8.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jilin Jian Yisheng Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.79%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.33x
- Recent ROE (2.33%) is below the historical average (7.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 9.83% | 10.37% | 0.67x | 1.42x | CN¥-397.47K |
| 2007 | 17.63% | 13.48% | 0.78x | 1.67x | CN¥15.63 Million |
| 2008 | 18.88% | 13.27% | 0.90x | 1.58x | CN¥19.45 Million |
| 2009 | 21.81% | 14.73% | 0.97x | 1.53x | CN¥33.10 Million |
| 2010 | 24.43% | 16.98% | 1.00x | 1.44x | CN¥51.77 Million |
| 2011 | 6.46% | 18.24% | 0.34x | 1.06x | CN¥-52.94 Million |
| 2012 | 6.16% | 16.09% | 0.36x | 1.06x | CN¥-60.26 Million |
| 2013 | 5.27% | 13.56% | 0.34x | 1.14x | CN¥-78.30 Million |
| 2014 | 5.57% | 12.24% | 0.32x | 1.44x | CN¥-76.64 Million |
| 2015 | 0.63% | 1.33% | 0.31x | 1.53x | CN¥-161.56 Million |
| 2016 | 0.76% | 1.41% | 0.35x | 1.53x | CN¥-160.89 Million |
| 2017 | 3.33% | 5.81% | 0.39x | 1.47x | CN¥-120.22 Million |
| 2018 | 3.72% | 7.08% | 0.38x | 1.38x | CN¥-116.48 Million |
| 2019 | 3.96% | 7.56% | 0.41x | 1.29x | CN¥-116.62 Million |
| 2020 | 4.01% | 9.50% | 0.30x | 1.40x | CN¥-119.51 Million |
| 2021 | 4.61% | 10.94% | 0.31x | 1.38x | CN¥-112.16 Million |
| 2022 | 3.86% | 10.01% | 0.28x | 1.38x | CN¥-132.40 Million |
| 2023 | 4.24% | 11.10% | 0.28x | 1.36x | CN¥-128.58 Million |
| 2024 | 2.33% | 7.79% | 0.23x | 1.33x | CN¥-171.47 Million |
Industry Comparison
This section compares Jilin Jian Yisheng Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) | CN¥2.32 Billion | 9.83% | 0.28x | $212.09 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |